{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:27:46Z","timestamp":1793824066391,"version":"4.6.1"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND:<\/jats:title>\n            <jats:p>Small cell neuroendocrine carcinoma of the cervix is a rare, aggressive tumor treated with a combination of surgery, chemotherapy, and radiation. Survival rates are poor, and innovative therapies are needed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CASE:<\/jats:title>\n            <jats:p>A 52-year-old woman was diagnosed with small cell neuroendocrine carcinoma of the cervix. Over a 10-year period, she was treated with six different systemic therapeutic regimens, underwent planned hysterectomy with bilateral salpingo-oophorectomy, and received radiation to the pelvis and brain. After a second recurrence of disease, she was treated with a combination of nivolumab and ipilimumab and experienced a complete and durable response.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION:<\/jats:title>\n            <jats:p>The combination of nivolumab and ipilimumab may represent a promising new treatment option for recurrent small cell neuroendocrine carcinoma of the cervix.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aog.0000000000004573","type":"journal-article","created":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T05:00:33Z","timestamp":1633669233000},"page":"813-816","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":28,"title":["Complete Response to Combination Nivolumab and Ipilimumab in Recurrent Neuroendocrine Carcinoma of the Cervix"],"prefix":"10.1097","volume":"138","author":[{"given":"Thomas A.","family":"Paterniti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Dorr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asad","family":"Ullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadyn","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharad","family":"Ghamande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,10,6]]},"reference":[{"key":"R1-20250423","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.ygyno.2016.12.003","article-title":"Neuroendocrine tumors of the uterine cervix: a therapeutic challenge for gynecologic oncologists","volume":"144","author":"Gadducci","year":"2017","journal-title":"Gynecol Oncol"},{"key":"R2-20250423","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1186\/s12885-018-4447-x","article-title":"Neuroendocrine carcinoma of the cervix: a systematic review of the literature","volume":"18","author":"Tempfer","year":"2018","journal-title":"BMC Cancer"},{"key":"R3-20250423","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1097\/AOG.0b013e318173570b","article-title":"Incidence, mortality, and prognostic factors of small cell carcinoma of the cervix","volume":"111","author":"Chen","year":"2008","journal-title":"Obstet Gynecol"},{"key":"R4-20250423","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/cncr.11086","article-title":"Prognostic factors in neuroendocrine small cell cervical carcinoma: a multivariate analysis","volume":"97","author":"Chan","year":"2003","journal-title":"Cancer"},{"key":"R5-20250423","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ygyno.2008.11.010","article-title":"Small cell neuroendocrine carcinoma of the cervix: analysis of outcome, recurrence pattern and the impact of platinum-based combination chemotherapy","volume":"112","author":"Zivanovic","year":"2009","journal-title":"Gynecol Oncol"},{"key":"R6-20250423","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.gore.2014.09.003","article-title":"Response to MEK inhibitor in small cell neuroendocrine carcinoma of the cervix with a KRAS mutation","volume":"10","author":"Lyons","year":"2014","journal-title":"Gynecol Oncol Rep"},{"key":"R7-20250423","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40661-017-0038-9","article-title":"Metastatic small cell neuroendocrine carcinoma of the cervix treated with the PD-1 inhibitor, nivolumab: a case report","volume":"4","author":"Paraghamian","year":"2017","journal-title":"Gynecol Oncol Res Pract"},{"key":"R8-20250423","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1634\/theoncologist.2016-0517","article-title":"Exceptional response to nivolumab and stereotactic body radiation therapy (SBRT) in neuroendocrine cervical carcinoma with high tumor mutational burden: management considerations from the center for personalized cancer therapy at UC San Diego Moores Cancer Center","volume":"22","author":"Sharabi","year":"2017","journal-title":"Oncologist"},{"key":"R9-20250423","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-19-3356","article-title":"A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART SWOG 1609) in patients with nonpancreatic neuroendocrine tumors","volume":"26","author":"Patel","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R10-20250423","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1158\/1078-0432.CCR-19-3014","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced neuroendocrine tumors: results from the phase II KEYNOTE-158 study","volume":"26","author":"Strosberg","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R11-20250423","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","article-title":"Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial [published errata appear in Lancet Oncol 2016;17:e270 and Lancet Oncol 2019;20(2):e70]","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol"},{"key":"R12-20250423","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ygyno.2016.02.008","article-title":"Natural history and outcome of neuroendocrine carcinoma of the cervix","volume":"141","author":"Margolis","year":"2016","journal-title":"Gynecol Oncol"},{"key":"R13-20250423","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ygyno.2016.10.040","article-title":"Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix","volume":"144","author":"Frumovitz","year":"2017","journal-title":"Gynecol Oncol"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000004573","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T18:03:04Z","timestamp":1745431384000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000004573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,6]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000004573","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10,6]]},"assertion":[{"value":"2021-06-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}